InnoCare Doses First Subject in U.S. TYK2 Inhibitor ICP-332 Trial

InnoCare Pharma (HKEX: 09969; SSE: 688428), a prominent biopharmaceutical company dedicated to cancer and autoimmune disease treatments, announced the commencement of a clinical trial for its innovative TYK2 (Tyrosine Kinase 2) inhibitor, ICP-332, in the United States. This marks the first dosing of a subject in this trial.

ICP-332, recognized for its potent and selective TYK2 inhibition, has shown promising results in previous studies. In a Phase II study conducted in China, ICP-332 met multiple efficacy endpoints for treating moderate-to-severe atopic dermatitis (AD). The results highlighted its impressive efficacy and safety profile. The efficacy of ICP-332 extends across various therapeutic classes and mechanisms of action for AD treatment, although these are not direct comparative studies. These significant findings were showcased at the 2024 American Academy of Dermatology (AAD) Annual Meeting through a late-breaking oral presentation.

It's noteworthy that, to date, no TYK2 inhibitors have received marketing approval for AD treatment globally. TYK2, a non-receptor tyrosine kinase and part of the JAK kinase family, plays a crucial role in the JAK-STAT signaling pathway, which is instrumental in the development of inflammatory diseases.

Dr. Jasmine Cui, Co-founder, Chairwoman, and CEO of InnoCare, emphasized the company's commitment to pioneering drugs in the autoimmune disease arena. Besides ICP-332, InnoCare has cultivated a robust pipeline of differentiated therapeutics with substantial global market potential. This includes orelabrutinib, a BTK inhibitor, ICP-488, a TYK2-JH2 inhibitor, and ICP-923, an IL-17 small molecule inhibitor. Dr. Cui reiterated the company's core value of "Science-driven innovation for the benefit of patients" and their dedication to accelerating clinical development. The ultimate goal is to ensure that their innovative drugs can benefit patients with autoimmune diseases promptly.

InnoCare is a commercial-stage biopharmaceutical entity focused on the discovery, development, and commercialization of first-in-class and/or best-in-class drugs specifically for cancer and autoimmune diseases with unmet medical needs, both in China and globally. The company maintains branches in several key locations, including Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States.